Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics Plc ADR (NQ: AUTL ) 4.430 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 4.430 Bid (Size) 4.420 (25) Ask (Size) 4.430 (4) Prev. Close 4.430 Today's Range 4.430 - 4.430 52wk Range 2.010 - 7.450 Shares Outstanding 52,346,231 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts June 17, 2024 Via Benzinga Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress June 14, 2024 From Autolus Therapeutics plc Via GlobeNewswire Performance YTD -35.23% -35.23% 1 Month +2.78% +2.78% 3 Month -8.47% -8.47% 6 Month -31.74% -31.74% 1 Year +72.37% +72.37% More News Read More Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget June 13, 2024 Via InvestorPlace Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO May 31, 2024 From Autolus Therapeutics plc Via GlobeNewswire Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views March 18, 2024 Via Benzinga Autolus Therapeutics's Earnings Outlook March 13, 2024 Via Benzinga Crude Oil Gains 1%; GameStop Shares Plunge May 17, 2024 Via Benzinga Exposures Fossil Fuels Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session May 17, 2024 Via Benzinga AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 17, 2024 Via InvestorPlace Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday May 17, 2024 Via Benzinga Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates May 17, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress May 14, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call May 13, 2024 From Autolus Therapeutics plc Via GlobeNewswire Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO April 24, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 April 23, 2024 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's After-Market Session April 11, 2024 Via Benzinga Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia April 02, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Changes to its Board of Directors April 01, 2024 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 20, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session March 15, 2024 Via Benzinga Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates March 14, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site March 12, 2024 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in Blood Cancer Journal March 11, 2024 From Autolus Therapeutics plc Via GlobeNewswire Earnings Scheduled For March 14, 2024 March 14, 2024 Via Benzinga Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 February 29, 2024 From Autolus Therapeutics plc Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
